Read this manager's filing book
Disclosed positions
Palo Alto Investors LP: source evidence dated 2026-08-20T03:59:59.999Z.
- Issuer
- PTC THERAPEUTICS INC
- Ticker
- PTCT
- Class
- COM
- Reported value
- $74,950,268
- Reported amount
- 918,846
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR/A: 0002073679-26-000102Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| PTC THERAPEUTICS INC | PTCT | COM | $74,950,268 | 918,846 | SH | None |
| ACADIA PHARMACEUTICALS INC | ACAD | COM | $72,461,629 | 2,864,096 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $44,138,548 | 413,980 | SH | None |
| MIRUM PHARMACEUTICALS INC | MIRM | COM | $40,834,953 | 348,808 | SH | None |
| ANAPTYSBIO INC | ANAB | COM | $40,735,508 | 603,489 | SH | None |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $39,068,500 | 682,777 | SH | None |
| DYNE THERAPEUTICS INC | DYN | COM | $36,591,441 | 1,647,521 | SH | None |
| UNITED THERAPEUTICS CORP | UTHR | COM | $33,911,514 | 62,587 | SH | None |
| DISC MEDICINE INC | IRON | COM | $30,473,488 | 416,646 | SH | None |
| BIOGEN INC | BIIB | COM | $30,308,681 | 140,279 | SH | None |
| IOVANCE BIOTHERAPEUTICS INC | IOVA | COM | $22,032,229 | 5,296,209 | SH | None |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $19,916,968 | 596,495 | SH | None |
| NOVOCURE LTD | NVCR | ORD SHS | $19,398,651 | 1,280,439 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $18,908,594 | 864,986 | SH | None |
| ANNEXON INC | ANNX | COM | $16,833,594 | 2,948,090 | SH | None |
| BICARA THERAPEUTICS INC | BCAX | COM | $16,341,614 | 550,408 | SH | None |
| CAREDX INC | CDNA | COM | $15,158,295 | 531,870 | SH | None |
| CELLDEX THERAPEUTICS INC | CLDX | COM NEW | $14,878,642 | 399,856 | SH | None |
| COMPASS THERAPEUTICS INC | CMPX | COM | $12,771,670 | 5,831,813 | SH | None |
| ALKERMES PLC | ALKS | SHS | $12,708,931 | 242,560 | SH | None |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | ORD SHS | $12,142,199 | 603,489 | SH | None |
| PROTHENA CORP PLC | PRTA | SHS | $11,191,487 | 1,143,155 | SH | None |
| TRAVERE THERAPEUTICS INC | TVTX | COM | $9,517,095 | 167,525 | SH | None |
| TAYSHA GENE THERAPIES INC | TSHA | COM SHS | $9,475,311 | 1,391,382 | SH | None |
| ACLARIS THERAPEUTICS INC | ACRS | COM | $8,535,045 | 1,613,430 | SH | None |
| AGIOS PHARMACEUTICALS INC | AGIO | COM | $7,926,733 | 213,601 | SH | None |
| CAPRICOR THERAPEUTICS INC | CAPR | COM NEW | $5,532,693 | 229,763 | SH | None |
| ALIGN TECHNOLOGY INC | ALGN | COM | $5,294,069 | 31,389 | SH | None |
| ORUKA THERAPEUTICS INC - Restricted | ORKA | COM | $3,192,573 | 33,546 | SH | None |
| XENON PHARMACEUTICALS INC | XENE | COM | $3,099,184 | 51,345 | SH | None |
| NEUROCRINE BIOSCIENCES INC | NBIX | COM | $3,053,349 | 18,117 | SH | None |
| EDWARDS LIFESCIENCES CORP | EW | COM | $3,043,074 | 33,640 | SH | None |
| STOKE THERAPEUTICS INC | STOK | COM | $2,769,126 | 84,631 | SH | None |
| CYTOKINETICS INC | CYTK | COM NEW | $2,742,692 | 32,195 | SH | None |
| PYXIS ONCOLOGY INC | PYXS | COMMON STOCK | $2,601,474 | 864,277 | SH | None |
| EHEALTH INC | EHTH | COM | $2,209,368 | 1,482,797 | SH | None |
| CRISPR THERAPEUTICS AG | CRSP | NAMEN AKT | $2,160,057 | 39,605 | SH | None |
| SAGIMET BIOSCIENCES INC-A | SGMT | COM SER A | $1,932,500 | 250,000 | SH | None |
| NUVATION BIO INC | NUVB | COM CL A | $1,855,139 | 326,609 | SH | None |
| BIONTECH SE-ADR | BNTX | SPONSORED ADS | $1,825,083 | 19,614 | SH | None |
| COMPASS PATHWAYS PLC ADR | CMPS | SPONSORED ADS | $1,635,966 | 115,616 | SH | None |
| HUMANA INC | HUM | COM | $1,582,922 | 3,985 | SH | None |
| NEWAMSTERDAM PHARMA CO NV | NAMS | ORDINARY SHARES | $1,503,327 | 44,359 | SH | None |
| VERASTEM INC | VSTM | COM NEW | $1,182,997 | 309,685 | SH | None |
| MADRIGAL PHARMACEUTICALS INC | MDGL | COM | $959,530 | 1,787 | SH | None |
| UROGEN PHARMA LTD | URGN | COM | $901,600 | 24,500 | SH | None |
| BICYCLE THERAPEUTICS PLC-ADR | BCYC | SPONSORED ADS | $856,014 | 201,890 | SH | None |
| XERIS BIOPHARMA HOLDINGS INC | XERS | COM | $826,927 | 104,410 | SH | None |
| ABEONA THERAPEUTICS INC | ABEO | COM NEW | $672,786 | 108,865 | SH | None |
| INSPIRE MEDICAL SYSTEMS INC | INSP | COM | $391,319 | 8,772 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.